Plasma exchange and glucocorticoid dosing in the treatment of anti-neutrophil cytoplasm antibody associated vasculitis (PEXIVAS): protocol for a randomized controlled trial

Michael Walsh, Peter A Merkel, Chen Au Peh, Wladimir Szpirt, Loïc Guillevin, Charles D Pusey, Janak De Zoysa, Natalie Ives, William F Clark, Karen Quillen, Jeffrey L Winters, Keith Wheatley, David Jayne, PEXIVAS Investigators

    207 Citationer (Scopus)

    Abstract

    Granulomatosis with polyangiitis (GPA, Wegener's) and microscopic polyangiitis (MPA) are small vessel vasculitides collectively referred to as anti-neutrophil cytoplasm antibody-associated vasculitis (AAV). AAV is associated with high rates of morbidity and mortality due to uncontrolled disease and treatment toxicity. Small randomized trials suggest adjunctive plasma exchange may improve disease control, while observational evidence suggests that current oral glucocorticoid doses are associated with severe infections in patients with AAV. A randomized study of both plasma exchange and glucocorticoids is required to evaluate plasma exchange and oral glucocorticoid dosing in patients with AAV.
    OriginalsprogEngelsk
    TidsskriftTrials
    Vol/bind14
    Sider (fra-til)73
    ISSN1745-6215
    DOI
    StatusUdgivet - 2013

    Fingeraftryk

    Dyk ned i forskningsemnerne om 'Plasma exchange and glucocorticoid dosing in the treatment of anti-neutrophil cytoplasm antibody associated vasculitis (PEXIVAS): protocol for a randomized controlled trial'. Sammen danner de et unikt fingeraftryk.

    Citationsformater